Concordance of assays designed for the quantification of JAK2V617F: a multicenter study
Open Access
- 1 January 2009
- journal article
- research article
- Published by Ferrata Storti Foundation (Haematologica) in Haematologica
- Vol. 94 (1) , 38-45
- https://doi.org/10.3324/haematol.13486
Abstract
Background Many different techniques have been designed for the quantification of JAK2V617F allelic burden, sometimes producing discrepant results. Design and Methods JAK2V617F quantification techniques were compared among 16 centers using 11 assays based on quantitative polymerase chain reaction (with mutation-specific primers or probes, or fluorescent resonance energy transfer/melting curve analysis), allele-specific polymerase chain reaction, conventional sequencing or pyrosequencing. Results A first series of blinded samples (granulocyte DNA, n=29) was analyzed. Seven assays (12 centers) reported values inside the mean±2SD; the mean coefficient of variation was 31%. Sequencing techniques lacked sensitivity, and strong discrepancies were observed with four techniques, which could be attributed to inadequate standards or to different modes of expression of results. Indeed, quantification of JAK2V617F in relation to another control gene produced higher than expected values, suggesting the possibility of more than two JAK2 copies/cell. After calibration of assays with common 1% to 100% JAK2V617F standards (dilutions of UKE-1 cells in normal leukocytes), 14 centers tested ten new samples. JAK2V617F allelic burdens greater or equal than 1% were then reliably quantified by five techniques – one allele specific-polymerase chain reaction and four TaqMan allele-specific quantitative polymerase chain reaction assays, including one previously giving results outside the mean±2SD – with a lower mean coefficient of variation (21%). Of these, only the two TaqMan allele-specific quantitative polymerase chain reaction assays with primer-based specificity could detect 0.2% JAK2V617F. Conclusions Techniques expressing the allelic burden as JAK2V617F/total JAK2 and using a common set of standards produced similar quantification results but with variable sensitivity. Calibration to a reference standard improved reproducibility.Keywords
This publication has 26 references indexed in Scilit:
- JAK2 V617F mutational status predicts progression to large splenomegaly and leukemic transformation in primary myelofibrosisBlood, 2007
- Numerical gain and structural rearrangements of JAK2, identified by FISH, characterize both JAK2617V>F-positive and -negative patients with Ph-negative MPD, myelodysplasia, and B-lymphoid neoplasmsExperimental Hematology, 2007
- Clinical profile of homozygous JAK2 617V>F mutation in patients with polycythemia vera or essential thrombocythemiaBlood, 2007
- Prospective identification of high-risk polycythemia vera patients based on JAK2V617F allele burdenLeukemia, 2007
- The quantitative JAK2 V617F neutrophil allele burden does not correlate with thrombotic risk in essential thrombocytosisLeukemia, 2007
- Quantitative Determination of JAK2 V617F by TaqMan: An Absolute Measure of Averaged Copies per Cell That May Be Associated with the Different Types of Myeloproliferative DisordersThe Journal of Molecular Diagnostics, 2007
- Comparison of whole blood vs purified blood granulocytes for the detection and quantitation of JAK2V617FLeukemia, 2007
- The JAK2 V617F mutation is detectable in granulocyte populations at greater than two copies per cell among individuals with myeloproliferative disordersLeukemia, 2007
- Polycythemia vera is not initiated by JAK2 mutationExperimental Hematology, 2007
- A sensitive and reliable semi‐quantitative real‐time PCR assay to detect JAK2 V617F in bloodHematological Oncology, 2006